Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
5.5 (1y: +4%)
Market Cap 221.51 M P/E(ttm)
Enterprise Value 212.65 M P/B 41.50
ANAC- NAS (USA)
Anacor Pharmaceuticals, Inc.
Not Rated
Top Ranked Predictable Companies
$5.50
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 1.773
ANAC's Cash to Debt is ranked lower than
71% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 46.63 vs. ANAC: 1.773 )
ANAC' s 10-Year Cash to Debt Range
Min: 1.35   Max: No Debt
Current: 1.77
Equity to Asset 0.094
ANAC's Equity to Asset is ranked lower than
84% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. ANAC: 0.094 )
ANAC' s 10-Year Equity to Asset Range
Min: -6.53   Max: 0.67
Current: 0.09
-6.53
0.67
F-Score: 1
Z-Score: -7.72
M-Score: -4.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -495.30
ANAC's Operating margin (%) is ranked lower than
80% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -31.50 vs. ANAC: -495.30 )
ANAC' s 10-Year Operating margin (%) Range
Min: -15647.7   Max: -34.1
Current: -495.3
-15647.7
-34.1
Net-margin (%) -522.2
ANAC's Net-margin (%) is ranked lower than
80% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -29.90 vs. ANAC: -522.2 )
ANAC' s 10-Year Net-margin (%) Range
Min: -15368.2   Max: -36.1
Current: -522.2
-15368.2
-36.1
ROE (%) -1165.8
ANAC's ROE (%) is ranked lower than
99% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. ANAC: -1165.8 )
ANAC' s 10-Year ROE (%) Range
Min: -1165.8   Max: -17.8
Current: -1165.8
-1165.8
-17.8
ROA (%) -109.8
ANAC's ROA (%) is ranked lower than
92% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. ANAC: -109.8 )
ANAC' s 10-Year ROA (%) Range
Min: -300.6   Max: -12
Current: -109.8
-300.6
-12
Revenue Growth (%) -53.8
ANAC's Revenue Growth (%) is ranked lower than
95% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ANAC: -53.8 )
ANAC' s 10-Year Revenue Growth (%) Range
Min: -53.8   Max: 193.7
Current: -53.8
-53.8
193.7
EBITDA Growth (%) -34
ANAC's EBITDA Growth (%) is ranked lower than
92% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ANAC: -34 )
ANAC' s 10-Year EBITDA Growth (%) Range
Min: -58.3   Max: -14
Current: -34
-58.3
-14
EPS Growth (%) -35.1
ANAC's EPS Growth (%) is ranked lower than
94% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ANAC: -35.1 )
ANAC' s 10-Year EPS Growth (%) Range
Min: -57   Max: -11.2
Current: -35.1
-57
-11.2
ยป ANAC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ANAC Guru Trades in

ANAC Guru Trades in

Q4 2012

ANAC Guru Trades in Q4 2012

Jean-Marie Eveillard 92,390 sh (New)
» More
Q1 2013

ANAC Guru Trades in Q1 2013

Jean-Marie Eveillard Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ANAC

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-03-31 Sold Out $3.15 - $6.52 $ 5.527%0
Jean-Marie Eveillard 2012-12-31 New Buy$4.6 - $6.81 $ 5.5-1%92390
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 41.50
ANAC's P/B is ranked lower than
98% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ANAC: 41.50 )
ANAC' s 10-Year P/B Range
Min: 3.77   Max: 41.5
Current: 41.5
3.77
41.5
P/S 18.32
ANAC's P/S is ranked lower than
69% of the 391 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. ANAC: 18.32 )
ANAC' s 10-Year P/S Range
Min: 6.7   Max: 180
Current: 18.32
6.7
180
EV-to-EBIT 11.1
ANAC's EV-to-EBIT is ranked lower than
92% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. ANAC: 11.1 )
ANAC' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 11.1

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 183.3
ANAC's Price/Net Current Asset Value is ranked lower than
85% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. ANAC: 183.3 )
ANAC' s 10-Year Price/Net Current Asset Value Range
Min: 26.9   Max: 173.3
Current: 183.3
26.9
173.3
Price/Tangible Book 42.3
ANAC's Price/Tangible Book is ranked lower than
96% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. ANAC: 42.3 )
ANAC' s 10-Year Price/Tangible Book Range
Min: 1.8   Max: 34.7
Current: 42.3
1.8
34.7
Price/Median PS Value 1.2
ANAC's Price/Median PS Value is ranked lower than
63% of the 345 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ANAC: 1.2 )
ANAC' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 7.1
Current: 1.2
0.6
7.1

Business Description

Anacor Pharmaceuticals, Inc. was incorporated in the state of Delaware on December 14, 2000. The Company is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company has discovered seven product candidates that have reached development. Its product candidates include two topically administered dermatologic compounds - tavaborole (formerly referred to as AN2690), an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory for the treatment of atopic dermatitis and psoriasis and it has discovered three compounds that it has out-licensed for further development- GSK2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria that is licensed to GlaxoSmithKline LLC, or GSK; AN8194, for the treatment of an animal health indication that is licensed to Eli Lilly and Company, or Lilly; and AN5568, also referred to as SCYX-7158, for human African trypanosomiasis (HAT, or sleeping sickness), which is licensed to Drugs for Neglected Diseases initiative, or DNDi. The Company's strategy is to drive rapid, efficient discovery of novel boron-based compounds, focus development activities, commercialize its products, leverage partnerships for non-core therapeutic areas and expand and protect its intellectual property. The Company competes with Novartis, Johnson & Johnson, Dow Pharmaceutical Sciences, LEO Pharma, Allergan and Galderma. The Company is also subject to various laws and regulations regarding laboratory practices.
Company Website
SEC Reports
Industry: Biotechnology
Compare:
Traded in other countries:44A.Germany
ยป More Articles for ANAC

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: GSVC, SHO, YAVY, CMCSA, ANAC May 16 2011 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial